Can Dynamic Contrast Enhanced Computed Tomography (DCE-CT) scans aid in the diagnosis of early stage lung cancer and are they cost effective?

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
28/05/2012		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
30/05/2012		[X] Results		
Last Edited	Condition category	[] Individual participant data		
16/03/2022	Cancer			

Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-at-2-different-ways-to-diagnose-lung-cancer-sputnik

Contact information

Type(s)

Scientific

Contact name

Prof Steve George

Contact details

Mailpoint 805
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT02013063

Secondary identifying numbers

HTA: 09/22/117

Study information

Scientific Title

Accuracy and cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography in the characterisation of solitary pulmonary nodules

Acronym

SPutNIk

Study objectives

A DCE-CT scan, either alone or in conjunction with fluorodeoxyglucose positron emission tomography (FDG-PET)/CT scan, can aid in the early diagnosis of lung cancer in patients where a single pulmonary nodule has been detected by conventional CT scan and that this is more cost effective than monitoring with conventional CT scans for up to two years.

More details can be found at http://www.hta.ac.uk/project/2790.asp

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Prospective observational study

Primary study design

Observational

Secondary study design

Other

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Diagnosis of early stage lung cancer in a population that have a single pulmonary nodule detected by conventional CT scan

Interventions

This is a diagnostic study involving the addition of a single DCE-CT scan, performed on the same day or within 2 weeks of a FDG-PET/CT scan which is standard NHS care for patients presenting with an SPN on conventional CT scan.

Patients will be followed up for a period of two years or until diagnosis under standard NHS care.

Outcomes of early stage lung cancer or not will be compared to scan data from DCE-CT scans ± FDG-PET/CT scans to assess accuracy of diagnosis and cost effectiveness of DCE-CT scans.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. Diagnostic test characteristics of sensitivity, specificity and accuracy for both FDG-PET/CT and DCE-CT scans in relation to a subsequent clinical diagnosis of lung cancer.
- 2. Economic model will include accuracy, estimated life expectancy, and quality adjusted life years (QALYs)
- 3. Costs will be estimated from an NHS perspective. Incremental cost-effectiveness ratios will compare management strategies with DCE-CT to strategies without DCE-CT.

Secondary outcome measures

- 1. Diagnostic test characteristics for FDG-PET/CT with incorporation of CT appearances and combined DCE-CT/FDG-PET scans.
- 2. Incidence of incidental extra-thoracic findings on FDG-PET/CT and subsequent investigations and costs will also be determined.

Overall study start date

01/09/2012

Completion date

30/04/2019

Eligibility

Key inclusion criteria

- 1. A soft tissue solitary dominant pulmonary nodule of ≥ 8 mm and ≤ 30 mm on axial plane, measured on lung window using conventional CT scan with no other ancillary evidence strongly indicative of malignancy (e.g. distant metastases) or unequivocal local invasion.
- 2. 18 years of age or over at time of providing consent
- 3. Able and willing to consent to study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

375

Total final enrolment

355

Key exclusion criteria

- 1. Pregnancy
- 2. History of malignancy within the past 2 years
- 3. Confirmed aetiology of the nodule
- 4. Biopsy of nodule prior to DCE-CT scan
- 5. Contra-indication to potential radiotherapy or surgery
- 6. Contra indication to scans (assessed by local procedures)

Date of first enrolment

01/09/2012

Date of final enrolment

16/12/2016

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Mailpoint 805

Southampton United Kingdom SO16 6YD

Sponsor information

Organisation

University Hospital Southampton NHS Foundation Trust (UK)

Sponsor details

Research and Development
SGH - Level E
Laboratory and Pathology Block
SCBR - MP 138
Southampton General Hospital
Southampton
England
United Kingdom
SO16 6YD

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/0485axj58

Funder(s)

Funder type

Government

Funder Name

NIHR Health Technology Assessment (HTA) (UK) (ref: 09/22/117)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article	results	01/11 /2020	03/11 /2020	Yes	No
<u>Protocol</u> <u>article</u>	protocol	14/10 /2016	17/12 /2020	Yes	No
Results article	Health Technology Assessment programme results publication	01/03 /2022	16/03 /2022	Yes	No